CXCL8 and prostate carcinoma: Metallothionein 2A is known to protect HeLa cells against ROS-induced death [30], whereas IL-8 inhibits TRAIL- and drug-induced apoptosis of prostate cancer cells [33] and increases tumorigenicity and metastatic potential of melanoma cells [32].